Department of Clinical Pharmacy, China Pharmaceutical University, Nanjing, Jiangsu, China.
Division of Respiratory Medicine, Department of Respiration, The Affiliated Drum Tower Hospital of Nanjing University Medical College, Nanjing University Medical School, Nanjing, Jiangsu, China.
Cancer Biomark. 2016;16(1):89-97. doi: 10.3233/CBM-150544.
Chemotherapy-related hepatic dysfunction affected the prognosis of non-small cell lung cancer (NSCLC). However, predictive factors of chemotherapy-related hepatic dysfunction remained undefined.
To identify the predictive factors for hepatic dysfunction during cytotoxic chemotherapy in Chinese patients with advanced NSCLC.
We retrospectively reviewed the medical records of patients with advanced NSCLC who received cytotoxic chemotherapy at Division of Respiratory Medicine, the affiliated Drum Tower Hospital of Nanjing University, from July 2012 to January 2015. We investigated the incidence of hepatic dysfunction during chemotherapy and evaluated several clinical factors that are associated with hepatic dysfunction, including body mass index (BMI) and high density lipoprotein cholesterol (HDL-C).
A total of 116 patients were enrolled in study, 54 patients (46.57%) experienced hepatic dysfunction after receiving chemotherapy. Multivariate analysis for hepatic dysfunction in patients with advanced NSCLC showed that hepatic dysfunction was associated with higher BMI (odds ratio = 4.742, P = 0.001) and lower HDL-C (odds ratio = 3.018, P = 0.019). Pearson's rank correlation analysis revealed that HDL-C and BMI presented a negative correlation in patients with hepatic dysfunction (r = -0.487, P < 0.001).
Higher BMI and lower HDL-C levels seem to be good independent predictive factors for chemotherapy-related hepatic dysfunction in advanced NSCLC. In addition, a negative correlation was presented between BMI and HDL-C.
化疗相关肝损伤影响非小细胞肺癌（NSCLC）的预后。然而，化疗相关肝损伤的预测因素仍不明确。
鉴定中国晚期 NSCLC 患者接受细胞毒性化疗时肝损伤的预测因素。
我们回顾性分析了 2012 年 7 月至 2015 年 1 月在南京大学附属鼓楼医院呼吸科接受细胞毒性化疗的晚期 NSCLC 患者的病历。我们调查了化疗期间肝损伤的发生率，并评估了与肝损伤相关的几个临床因素，包括体重指数（BMI）和高密度脂蛋白胆固醇（HDL-C）。
共纳入 116 例患者，54 例（46.57%）在接受化疗后发生肝损伤。多变量分析显示，BMI 较高（比值比=4.742，P=0.001）和 HDL-C 较低（比值比=3.018，P=0.019）与晚期 NSCLC 患者的肝损伤相关。Pearson 秩相关分析显示，肝损伤患者的 HDL-C 和 BMI 呈负相关（r=-0.487，P<0.001）。
较高的 BMI 和较低的 HDL-C 水平似乎是晚期 NSCLC 患者化疗相关肝损伤的良好独立预测因素。此外，BMI 和 HDL-C 之间存在负相关。
